Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$8.9M
8M shares
52-week range
$0.68 – $2.39
24% from low
Exchange
NASDAQ
ADRC
Borrow rate
19.76%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $2.4M | $2.5M | $145.8K | $765.2K | $1.8M | $4.9M | $7.3M |
| Cost of revenue | $582.3K | $680.8K | $688.8K | $810.8K | $241.7K | $64.6K | $1.6M | $2.5M |
| Gross profit | $1.3M | $1.7M | $1.8M | −$665.1K | $523.5K | $1.7M | $3.3M | $4.8M |
| Gross margin | 68.4% | 71.5% | 72.6% | -456.2% | 68.4% | 96.4% | 68.1% | 65.4% |
| R&D | $2.3M | $1.0M | $1.2M | $1.4M | $657.7K | $2.6M | $5.4M | $3.6M |
| Operating income | −$3.0M | −$4.7M | −$2.9M | −$8.4M | −$2.9M | −$3.6M | −$5.8M | −$5.3M |
| EBITDA | −$3.2M | −$4.7M | −$3.1M | −$8.0M | −$3.1M | −$3.4M | −$5.2M | −$5.3M |
| Net income | −$3.0M | −$4.7M | −$2.9M | −$8.4M | −$2.9M | −$3.8M | −$6.9M | −$5.2M |
| Net margin | -163.4% | -195.0% | -116.2% | -5751.6% | -373.0% | -209.8% | -141.5% | -71.6% |
| EPS (diluted) | -0.90 | -1.29 | -0.66 | -1.52 | -0.50 | -0.66 | -1.22 | -0.90 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2027 | $9M | $-0.02 | $-0.02–$-0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
www.immuron.com.auNo one on the platform currently holds IMRN.
No tracked institution reports a position in IMRN as of their last filing.
No one on the platform has traded IMRN yet.
| $8M |
| — |
| COCPCocrystal Pharma, Inc. | $1.03 | +0.98% | $11M | — |
| DWTXDogwood Therapeutics, Inc. | $1.78 | +7.88% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$BOLD i met their CEO at ASCO 2023… hmm 🤔 $CCCC $IMRN $SLS
View on StockTwits ↗$IMRN wow only 8 mil shares and someone failed to deliver 10% of them recently. Never seen anything like that… Looks like someone borrowed and lost their buddy’s shares? Upward pressure remains
View on StockTwits ↗$IMRN Nice! Finally some action today after long consolidation and holding up 13%+ gains. This is just the begining and volume shuld come in gradually as this raises slowly. Great chart set up with tonn of shorts stuck here without liquidity to exit. Action in the coming days could get very interesting!
View on StockTwits ↗$IMRN whoever is spoofing this sht should go to jail. The ask is total BS, good luck getting a fill at what is listed.
View on StockTwits ↗$IMRN 4 hr candle is showing double bottom at 1.05 and has been consolidating above 1 for the past 2+ weeks. A rise here is imminent in the coming days/weeks with or without news.
View on StockTwits ↗$IMRN short interest will update again based on end of today. Someone isn’t finding shares and is losing their patience, probably try to whipsaw it before they begin paying for what they can’t find with fud tactics. Very limited playbook when you look at the shares available and borrow rates, especially after the Australian exchange sent the inquiry recently about unusual trading. Ask yourself why someone would risk manipulating a stock under 10 mil with multiple DOD contracts recently awarded, something is probably coming that justified the risk
View on StockTwits ↗$IMRN Absolutely. This is consolidating heavily above 1.1 levels just like last time before it raised heavily. Round 2 is in the corner in the coming days. PAYtience will pay here!
View on StockTwits ↗$IMRN wow- 532000 shares short! 10 days to cover. Less than 100K shares to borrow going on a week now, borrow rate still over 30% ⏰ tick tock
View on StockTwits ↗$IMRN Absolutely. Even inspite of thick red market, this had a strong 4 hr green candle. Consistent higher lows chart pattern in a bullish wedge and is consolidating for the next leg up in the coming days IMO.
View on StockTwits ↗$IMRN very nice short on this manufactured poop stock the irony play pills may prevent poopy pants, but the stock took a big ugly dump like i said it would im never wrong kids
View on StockTwits ↗$IMRN Absolutely. Just a matter of time. 1.2 is good support and should reverse from there IMO.
View on StockTwits ↗$IMRN So you're the new board pumper now? Welcome. But that won't change much.
View on StockTwits ↗$IMRN Need some volume or action here. Looks better than yesterday close. Wen news PR drop on this one? Lets Go!
View on StockTwits ↗$IMRN ADR’s aren’t going to R/S 🤣 love the idiots who don’t understand dual exchange dynamics. There was no R/S my sad friend. Nearly a point a week that shorts are paying to borrow… now that’s something real
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 0.8× sales vs its 6.2× historical median P/S.
Fair value ≈ $8.94 · price $1.08 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.